Adamas Investor Day

September 18, 2017

Commercial plans and market opportunity for their recently approved drug (GOCOVRI™) for the treatment

of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, and an overview of the pipeline products.

 

Date:  September 18, 2017

Time:  8:00AM - 11:00AM

 

Guest Speaker:

Rajesh Pahwa, MD, Laverne & Joyce Rider
Professor of Neurology at the Kansas Medical Center and Director,
Parkinson's Disease Center of Excellence at the University of Kansas Health System

 

For more information or to RSVP, please contact Marcy Nanus (mnanus@troutgroup.com)

Register / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Adamas Pharmaceuticals, Inc. ADMS
Fo­cused on treat­ing time-de­pen­dent dis­ease symp­toms of CNS di­s­or­ders by de­vel­op­ing nov­el chrono-synchro­nous ther­a­peu­tic so­lu­tions as sin­gle agent drugs and fixed dose com­bi­na­tions. The Com­pany... [more in­for­ma­tion]